Trial Information

Summary: Patients with Advanced Endometrial Cancer for Clinical Trial

The Cancer Center at the University of Virginia invites women with advanced stage or recurrent endometrial cancer to enroll in a clinical study.

This type of cancer is typically treated with chemotherapy with the three-drug combination of cisplatin, doxorubicin, and paclitaxel. Some doctors, while using chemotherapy, choose the two-drug combination of carboplatin and paclitaxel to treat patients. The purpose of the study is to compare these two different drug combinations to see if there is any difference between the two-drug and three-drug chemotherapy combinations. Participants will be assigned randomly to receive one or the other drug combinations. If you receive the three-drug combination, you will receive chemotherapy for two days. This schedule will be repeated every 21 days for 7 treatments, as long as your response is favorable. If you are assigned to receive the two-drug combination, you will receive chemotherapy for one day only. This schedule of treatments will be repeated every 21 days for 7 treatments as long as your response is favorable.

Before and during the study, participants will undergo heart function tests, hearing tests, pelvic examinations, blood tests, urine tests, chest x-rays, and a CT or MRI scan. Participants will be followed indefinitely (for over three years) to determine the long-term side effects of the drug combinations and the impact the drug combinations have on cancer progression.

The participants insurance will be billed for all procedures, tests and medications. There is no financial compensation for study participation.

For more information, please contact:
Heather Lothamer
434-924-2745 or hll5y@virginia.edu
Principal Investigator: Willie Andersen, MD
HIC 11399/GOG 209



www.healthsystem.virginia.edu/clinical_trials

If you would like to learn more about participating in this study, please send an e-mail message using the form below.